315 related articles for article (PubMed ID: 24195603)
21. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy.
Avedillo Díez I; Zychlinski D; Coci EG; Galla M; Modlich U; Dewey RA; Schwarzer A; Maetzig T; Mpofu N; Jaeckel E; Boztug K; Baum C; Klein C; Schambach A
Mol Pharm; 2011 Oct; 8(5):1525-37. PubMed ID: 21851067
[TBL] [Abstract][Full Text] [Related]
22. Foamy virus vectors: an awaited alternative to gammaretro- and lentiviral vectors.
Rethwilm A
Curr Gene Ther; 2007 Aug; 7(4):261-71. PubMed ID: 17969559
[TBL] [Abstract][Full Text] [Related]
23. Lentiviral vectors.
Loewen N; Poeschla EM
Adv Biochem Eng Biotechnol; 2005; 99():169-91. PubMed ID: 16568892
[TBL] [Abstract][Full Text] [Related]
24. Lentivirus and foamy virus vectors: novel gene therapy tools.
Pandya S; Klimatcheva E; Planelles V
Expert Opin Biol Ther; 2001 Jan; 1(1):17-40. PubMed ID: 11727544
[TBL] [Abstract][Full Text] [Related]
25. Hematopoietic-specific lentiviral vectors circumvent cellular toxicity due to ectopic expression of Wiskott-Aldrich syndrome protein.
Toscano MG; Frecha C; Benabdellah K; Cobo M; Blundell M; Thrasher AJ; García-Olivares E; Molina IJ; Martin F
Hum Gene Ther; 2008 Feb; 19(2):179-97. PubMed ID: 18240968
[TBL] [Abstract][Full Text] [Related]
26. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
Sinn PL; Sauter SL; McCray PB
Gene Ther; 2005 Jul; 12(14):1089-98. PubMed ID: 16003340
[TBL] [Abstract][Full Text] [Related]
27. Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy.
Papayannakos C; Daniel R
Gene Ther; 2013 Jun; 20(6):581-8. PubMed ID: 23171920
[TBL] [Abstract][Full Text] [Related]
28. Strategies for retargeted gene delivery using vectors derived from lentiviruses.
Bartosch B; Cosset FL
Curr Gene Ther; 2004 Dec; 4(4):427-43. PubMed ID: 15578992
[TBL] [Abstract][Full Text] [Related]
29. Integrase-defective lentiviral vectors--a stage for nonviral integration machineries.
Staunstrup NH; Mikkelsen JG
Curr Gene Ther; 2011 Oct; 11(5):350-62. PubMed ID: 21745178
[TBL] [Abstract][Full Text] [Related]
30. Toward integrase defective lentiviral vectors for genetic immunization.
Negri DR; Michelini Z; Cara A
Curr HIV Res; 2010 Jun; 8(4):274-81. PubMed ID: 20353396
[TBL] [Abstract][Full Text] [Related]
31. Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research.
Dropulić B
Hum Gene Ther; 2011 Jun; 22(6):649-57. PubMed ID: 21486177
[TBL] [Abstract][Full Text] [Related]
32. The Old and the New: Prospects for Non-Integrating Lentiviral Vector Technology.
Luis A
Viruses; 2020 Sep; 12(10):. PubMed ID: 33003492
[TBL] [Abstract][Full Text] [Related]
33. Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes.
Zhou S; Fatima S; Ma Z; Wang YD; Lu T; Janke LJ; Du Y; Sorrentino BP
Mol Ther; 2016 Jun; 24(6):1090-1099. PubMed ID: 26957223
[TBL] [Abstract][Full Text] [Related]
34. Non-integrating lentiviral vectors based on the minimal S/MAR sequence retain transgene expression in dividing cells.
Xu Z; Chen F; Zhang L; Lu J; Xu P; Liu G; Xie X; Mu W; Wang Y; Liu D
Sci China Life Sci; 2016 Oct; 59(10):1024-1033. PubMed ID: 27614752
[TBL] [Abstract][Full Text] [Related]
35. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
[TBL] [Abstract][Full Text] [Related]
36. Advances in lentiviral vectors: a patent review.
Picanco-Castro V; de Sousa Russo-Carbolante EM; Tadeu Covas D
Recent Pat DNA Gene Seq; 2012 Aug; 6(2):82-90. PubMed ID: 22670608
[TBL] [Abstract][Full Text] [Related]
37. Lentiviral vectors and gene therapy.
Klimatcheva E; Rosenblatt JD; Planelles V
Front Biosci; 1999 Jun; 4():D481-96. PubMed ID: 10352135
[TBL] [Abstract][Full Text] [Related]
38. Non-integrating lentiviral vectors.
Sarkis C; Philippe S; Mallet J; Serguera C
Curr Gene Ther; 2008 Dec; 8(6):430-7. PubMed ID: 19075626
[TBL] [Abstract][Full Text] [Related]
39. Strategies for targeting lentiviral vectors.
Frecha C; Szécsi J; Cosset FL; Verhoeyen E
Curr Gene Ther; 2008 Dec; 8(6):449-60. PubMed ID: 19075628
[TBL] [Abstract][Full Text] [Related]
40. Integrating Vectors for Gene Therapy and Clonal Tracking of Engineered Hematopoiesis.
Biasco L; Rothe M; Schott JW; Schambach A
Hematol Oncol Clin North Am; 2017 Oct; 31(5):737-752. PubMed ID: 28895844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
